Zai Lab Ltd (ZLAB) stock is soaring 5.01% in intraday trading on Thursday, following the release of its first-quarter 2025 financial results. The biopharmaceutical company reported a narrower-than-expected loss per share, despite missing revenue estimates.
For the quarter ended March 31, Zai Lab posted an adjusted loss of $0.45 per American depositary share, beating the Wall Street consensus estimate of a $0.55 loss. The company's revenue rose 22.2% year-over-year to $106.49 million, falling short of analysts' expectations of $113.15 million. Despite the revenue miss, investors appear encouraged by the improved bottom line and the company's maintained full-year guidance.
Zai Lab reiterated its full-year 2025 revenue guidance of $560 million to $590 million, in line with analysts' expectations of $565.4 million. The company's ability to narrow its losses while maintaining its revenue outlook seems to have boosted investor confidence, driving the stock's significant uptick. This positive momentum comes after a challenging period, as Zai Lab shares had fallen by 21.5% in the previous quarter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.